Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C93/3 genotypes.

Clinical pharmacology and therapeutics - 1 Nov 2006

Fukuda Tsuyoshi, Tanabe Tomoko, Ohno Masako, Tougou Katsuhiko, Fujio Yasushi, Azuma Junichi, Yamamoto Isamu, Takeda Akira

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9
Share to Hemorrhage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mixed Function Oxygenases

Share to Stereoisomerism

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 17112813
DOI: 10.1016/j.clpt.2006.08.005

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.PMID 17112813Read ↗

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patientsSemantic proximity Read ↗

VKORC1 and CYP2C9 genotype distribution in Asian countries.Semantic proximity Read ↗

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.Semantic proximity Read ↗

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.Semantic proximity Read ↗

The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients.Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.Semantic proximity Read ↗

Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients.Semantic proximity Read ↗

[Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.